Your session is about to expire
← Back to Search
Pancreatic Ductal Adenocarcinoma for Pancreatic Cancer
N/A
Recruiting
Led By Kersten Schroeder, PhD
Research Sponsored by University of Central Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Study Summary
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pancreatic Ductal AdenocarcinomaExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
University of Central FloridaLead Sponsor
79 Previous Clinical Trials
1,098,336 Total Patients Enrolled
Kersten Schroeder, PhDPrincipal InvestigatorUniversity of Central Florida
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger